anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Measurement of creatinine to determine eGFR before intravascular iodinated contrast administration is indicated to assess whether a patient is at risk of contrast-induced acute kidney injury (AKI). For patients with reduced eGFR intravenous hydration can be offered before the scan to reduce the risk of AKI. If no recent eGFR measurement is available, contrast procedures could be cancelled and rescheduled while a creatinine test is processed in the laboratory. Using POC creatinine tests before contrast-enhanced procedures could minimise the risk of kidney injury, and may reduce the number of cancelled scans. The question is whether POC creatinine assay is accurate and beneficial in this setting compared to the standard laboratory assay.

The i-STAT Alinity POC creatinine device is one of three devices which calculate estimated glomerular filtration rate (eGFR) recommended in clinical practice guidelines to assess kidney function to guide decisions on the use of intravascular iodinated contrast in adults. In the study, i-STAT Alinity POC measurements of creatinine will be performed using already available blood samples of patients with estimated eGFR\<30 ml/min/1.73m2 and mean difference between eGFR and serum creatinine measurements using POC and standard laboratory assays will be calculated. Results will be used to evaluate the agreement between of POC and laboratory assays on risk stratification (i.e., the percentage of patients with eGFR\<30 according to both laboratory and POC assays) and post-contrast acute kidney injury (AKI; i.e., the percentage of patients with post-contrast acute kidney injury according to both laboratory and POC assays). Finally, the number of elective procedures which are delayed (including delayed planning) or cancelled because a serum creatinine assay is required and unavailable will be prospectively evaluated for Maastricht UMC+ in this study.
The invention discloses a traditional Chinese medicine capsule for treating impotence and premature ejaculation. The capsule is composed of the following traditional Chinese herbals in parts by weight: 80 to 110 parts of radix astragali, 80 to 110 parts of red sage root, 40 to 70 parts of ligusticum wallichii, 50 to 70 parts of achyranthes root, 50 to 70 parts of red peony root, 35 to 55 parts of Chinese angelica, 20 to 40 parts of peach seed, 35 to 55 parts of morinda officinalis, 50 to 80 parts of cistanche, 20 to 40 parts of armadillo scale, 25 to 40 parts of physochlaina macrophylla, 10 to 20 parts of Chinese magnoliavine, 20 to 35 parts of flastem milkvetch seed, and 30 to 50 parts of mantis egg-case. The capsule is prepared by the following steps: screening, washing, and drying the raw materials mentioned above, processing, grinding, sieving with a 120-mesh sieve, and finally filling a certain amount of powder in empty capsules so as to obtain the finished product. The impotence and premature ejaculation is treated on the theory basis of qi and blood, the traditional Chinese herbals having the functions of activating blood and removing stasis are used to free the collaterals and vessels, moreover, traditional Chinese herbals having the function of enriching blood are used to enrich the blood, thus the blood and qi are sufficient, qi circulation is not impeded, thus the blood circulation is unhindered, and the unimpeded qi and blood circulation is the basis of treatment on impotence and premature ejaculation. The practices have proved that most patients can erect, the sperm motility is increased, or the patients are evenly cured, after 2 to 5 treatment courses. The capsule has the advantages of rapid effect, short treatment course, and prominent curative effect.
Due to the improvement of screening techniques, the detection of peripheral and isolated lesions is an increasingly frequent situation. However these SPN cause difficulties in obtaining a sample. Indeed, current endoscopic techniques remain insufficient in terms of performance. Moreover, computed tomography-guided percutaneous needle biopsy despite a very good sensitivity has many limitations related to the size of the lesions, the accessibility and important complications. The Archimedes® system is an improved version of LungPoint® and combines 3D reconstruction of chest images with intraoperative radioscopy. It uses a catheter to access through the bronchial wall the pulmonary parenchyma and navigate to the SPN. All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure. Patients' participation in the study will stop once they benefit from their thoracic surgery
A process for the production of an extract of a residue of Lithothamnion species wherein the residue of Lithothamnion has had siliceous materials and debris removed, been bleached, cleansed, and sterilised is provided, wherein the process comprises treating the residue with acid at pH of 3.8-5 in the presence of an anti-foaming agent as defined therein. The acid may be selected from acetic, lactic, tartaric, sulphuric, hydrochloric, citric, malic acid or mixture thereof. A composition derived from lithothamnion species by treatment with acid which contains at least 12 wt% calcium and at least 1 wt% magnesium is also provided wherein the composition has the colour, solubility, taste, and odour properties defined therein. The composition has anti-inflammatory activity in a murine bone derived macrophage cell model primed for a pro-inflammatory response with LPS. The composition may be used in a pharmaceutical composition or a food supplement. A method of reducing the amount of statin required to reduce cholesterol levels in a subject by co-administration of the composition together with a statin is provided. A method of treating an inflammatory disease such as atherosclerosis, ulcerative colitis, osteoarthritis, irritable bowel syndrome, Crohn’s disease, psoriasis, eczema, or epidermolysis is provided.
Fespixon cream contains 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%) with appearance in yellow-green to light green color. Fespixon cream will be applied twice daily for up to 12 weeks to the linear wound.
<P>PROBLEM TO BE SOLVED: To prepare a cosmetic which sufficiently improves the state of the hydrogen bond in the hair.  <P>SOLUTION: This cosmetic comprises (a) an amino acid pendant type polymer and (2) a polyoxyethylene polyoxypropylene glyceryl ether and is used for treating untidy hair caused by variation in the hydrogen bond in the hair to improve the state of the hydrogen bond in the hair. A homopolymer containing a basic amino acid as an amino acid pendant is especially preferable as the amino acid pendant type polymer. Lysine may be especially preferably cited as the basic amino acid. The average addition mol number of the oxyethylene group of the polyoxyethylene polyoxypropylene glyceryl ether is preferably 10-30, more preferably 15-25 and the average addition mol number of the oxypropylene group is preferably 1-30, more preferably 15-25.  <P>COPYRIGHT: (C)2004,JPO
Disclosed is a vaccine for non-human animals, which can effectively induce immunity in a non-human animal such as a farm animal and a poultry. The vaccine for non-human animals according to the present invention contains a liposome having, coupled to the surface thereof, an antigen molecule derived from a pathogen capable of affecting a non-human animal. The non-human animal is, for example, a farm animal or a poultry. An infectious bronchitis virus (IBV) vaccine, which is one of the most preferred embodiments of the vaccine of the present invention, is effective against various isolated IBV strains, and is expected to be sufficiently available in the case where a mutant strain occurs. A PRRSV vaccine, which is another preferred embodiment of the vaccine of the present invention, is confirmed to have an effect to alleviate fever due to an infection or reduce the formation of a lesion in the lung and the like. According to the present invention, it becomes possible to develop a liposome vaccine effective for the prevention of infections with pathogens for various non-human animals, such as IBV and PRRSV.
Low back pain (LBP) is a significant global health challenge due to its high prevalence, and chronicity and recurrence rates, with projections suggesting an increase in the next years due to population growth and aging. The chronic and recurrent nature of LBP, responsible for a significant percentage of years lived with disability, underscores the need for effective management strategies, including self-management strategies advocated by current guidelines, to empower patients and potentially improve healthcare efficiency and clinical outcomes. Therefore, the aim of this study was to analyze the added value of face-to-face visits in patients with chronic LBP undergoing a self-management program based on therapeutic exercises on pain intensity, disability, quality of life and treatment adherence and satisfaction. A randomized clinical trial was conducted, allocating 49 patients into a experimental group with a mobile health (mHealth) app usage and face-to-face sessions and 49 patients into an active control group without face-to-face sessions. Pain intensity, disability and quality of life were assessed at baseline, 4 weeks postintervention and 12 weeks postintervention. Patients' satisfaction and adherence were assessed at the end of the study. The multivariate general model revealed no statistically significant time × group interaction for any outcome (p > 0.0068) but mental quality of life (p = 0.006). Within-group differences revealed significant improvements for all the clinical indicators (all, p < 0.001). Patients allocated to the experimental group reported greater satisfaction and adherence (both, p < 0.001) compared to the control group. The use of mHealth apps such as Healthy Back® as part of digital health initiatives may serve as a beneficial approach to enhance the management of LBP.
Non-purging compensatory behaviors (NPCB; e.g. driven exercise, fasting, other extreme behaviors) are a subcategory of compensatory behaviors typically characterized as infrequent and less severe. Limited prior research has studied NPCB despite their increasing prevalence among adults with binge-spectrum eating disorders (B-ED). More research is needed to understand the types of NPCB present among B-ED and the association between NPCB, clinical severity, and treatment outcomes. Secondary analyses were conducted among 155 adults with B-ED in cognitive-behavioral (CBT)-based clinical trials. At baseline and post-treatment, clinical interviews of eating pathology assessed binge eating frequency, purging compensatory behavior frequency, and global eating pathology. The following NPCB were also assessed: driven exercise, 24-h fasting, 8+ waking hours of compensatory fasting, chewing and spitting, and other extreme weight control behaviors. Participants engaging in NPCB reported higher global eating pathology than those not engaging in NPCB. Frequency of chewing and spitting and 24-h fasting significantly decreased over treatment. Engagement in NPCB at baseline did not predict CBT outcomes. The current study highlights the prevalence and clinical severity of NPCB in B-ED but offers promising results regarding the potential for CBT to improve these behaviors. More research is needed on other extreme weight control behaviors reported qualitatively in our sample and on the maintenance of improvements in non-purging behaviors after CBT.
BACKGROUND: Impairment of kidney function is one of the long-term sequelae of hypertension and it contributes to increased morbidity and mortality in hypertensive patients. Left ventricular hypertrophy (LVH) is a common complication of hypertension which can worsen the outcome in affected patients. This study was designed to compare kidney function in hypertensive patients with LVH with that in hypertensive patients without LVH.
METHODS: The study was conducted among hypertensive patients attending cardiology clinics at two tertiary hospitals in Nigeria. A questionnaire was used to obtain demographic and clinical information from the participants. Kidney function was determined by measuring serum urea and creatinine, urinary creatinine and microalbumin. Echocardiography was performed to detect LVH. Results of kidney function tests were compared between participants who had LVH and those who did not.
RESULTS: Of the 105 participants recruited, 58 (55.2%) were males. The median age of all participants was 52 (interquartile range (IQR) 40-61) years and LVH was confirmed in 48 (45.7%) of them. Participants with LVH were older (55 vs 49 years; p=0.02) but had lower weight (74 vs 78 kg; p=0.04). Participants without LVH had higher microalbuminuria (5.2 vs 4.05 mg/dl; p=0.03), lower estimated glomerular filtration rate (62 vs 92 ml/min/1.73 m2; p=0.004), and higher stages of CKD.
CONCLUSION: Hypertensive patients with LVH had lower levels of microalbuminuria, higher estimated GFR, and lower stages of CKD compared to those with no LVH.
The hypothesis is that the individual transfusion strategies will help to save blood resource, and meanwhile will not adversely affect the patients' clinical outcomes. Participants will be randomly divided into two groups, where the strategies of transfusion of red blood cell will be made following different principles. The strategies for patients in control group will be made by the attending doctors in charge according to the current Chinese red blood cell transfusion guidelines. For the patients in study group, the clinical condition will be identified every time red blood cell transfusion is considered. The strategies will be made according to the comparison between the score and the Hb concentration. The volume of the red blood cell used in these two groups will be compared. The number of patients who need transfusion in these two groups will be compared. The clinical outcomes will also be compared between the two groups.
The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride, and do not contain such agents. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.
PURPOSE:A syrup agent, containing lysozyme or a salt thereof as an active constituent, using only white sugar as a glucide of a base thereof and capable of stabilizing a pharmaceuticall by keeping the pH thereof within a specific range. CONSTITUTION:A lysozyme syrup agent containing lysozyme or a salt thereof as an active constituent, using only white sugar as a glucide of a base thereof with the pH kept at 4.7-6. If a single syrup is used as the syrup base thereof to prepare the syrup agent, there is a disadvantage that the activity of the lysozyme is reduced with time and colored, etc. If D-sorbit or xylitol, etc., is used, there is a disadvantage that diarrheal symptoms are caused, etc. The use of the white sugar to keep the pH within 4.7-6 range improves remarkably the stability with time. The amount of the white sugar to be incorporated is 20-60wt% used on the total amount, and the pH is adjusted by using an ordinary pH adjustor, e.g. citric acid.
ApcMin/+ mouse was a model mouse for human familial adenomatous polyposis, and irradiation at an early age increases tumors in the small and large intestine. To study the effects of antioxidant administration on tumor incidence after continuous whole-body exposure to gamma rays, ApcMin/+ mice were exposed to a medium-dose-rate, 200 mGy/d, from postnatal Day 0 to 21 of age or a high-dose-rate of 0.65 Gy/min (total dose 4.2 Gy) on postnatal Day 7. The dams and pups were supplied with the N-acetylcysteine (NAC) in drinking water (7 g/L), from gestation Day 15 until weaning (21 days-old). A significant increase in the number of intestinal tumors were observed in ApcMin/+ mice irradiated with high dose-rate gamma rays as compared with the non-irradiated controls, but there was no significant difference in tumor counts between the non-irradiated controls and the medium-dose rate irradiation groups. NAC administration did not have any significant effect at least at this dose. These results suggest that the supplementation of anti-oxidant at the early stage of tumorigenesis does not suppress the formation of irradiation-induced small intestinal tumors.
The usual maintenance dose is in the range of 0.75 to 12 mg daily, which may be given as a single dose or in divided doses (see Dosage Interval). Dosage increases should be made in increments of no more than 1.5 mg at weekly intervals based upon the patient’s blood glucose response.

No exact dosage relationship exists between glyburide tablets (micronized), USP and the other oral hypoglycemic agents, including nonmicronized glyburide tablets. Although patients may be transferred from the maximum dose of other sulfonylureas, the maximum starting dose of 3 mg of glyburide tablets (micronized), USP should be observed. A maintenance dose of 3 mg of glyburide tablets (micronized), USP provides approximately the same degree of blood glucose control as 250 to 375 mg chlorpropamide, 250 to 375 mg tolazamide, 5 mg of glyburide (nonmicronized tablets), 500 to 750 mg acetohexamide, or 1000 to 1500 mg tolbutamide.

When transferring patients receiving more than 40 units of insulin daily, they may be started on a daily dose of glyburide tablets (micronized), USP 3 mg concomitantly with a 50% reduction in insulin dose. Progressive withdrawal of insulin and increase of glyburide tablets (micronized), USP in increments of 0.75 to 1.5 mg every 2 to 10 days is then carried out. During this conversion period when both insulin and glyburide tablets (micronized), USP are being used, hypoglycemia may rarely occur. During insulin withdrawal, patients should test their urine for glucose and acetone at least three times daily and report results to their physician. The appearance of persistent acetonuria with glycosuria indicates that the patient is a Type I diabetic who requires insulin therapy.

### Concomitant Glyburide and Metformin Therapy

Glyburide tablets (micronized), USP should be added gradually to the dosing regimen of patients who have not responded to the maximum dose of metformin monotherapy after four weeks (see Usual Starting Dose and Titration to Maintenance Dose). Refer to metformin package insert.

With concomitant glyburide and metformin therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug. However, attempts should be made to identify the optimal dose of each drug needed to achieve this goal. With concomitant glyburide and metformin therapy, the risk of hypoglycemia associated with sulfonylurea therapy continues and may be increased. Appropriate precautions should be taken (see PRECAUTIONS).
Patients receiving immunosuppressants, including mycophenolic acid delayed release, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6) ]. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. 

As usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a broad-spectrum sunscreen with a high protection factor.

Post-transplant lymphoproliferative disorder (PTLD) has been reported in immunosuppressed organ transplant recipients. The majority of PTLD events appear related to Epstein-Barr Virus (EBV) infection. The risk of PTLD appears greatest in those individuals who are EBV seronegative, a population which includes many young children.
PURPOSE:To provide a carcinostatic agent containing lambda-spirulinan which is a sugar produced by an algae Spirulina subsalsa. CONSTITUTION:The objective carcinostatic agent can be produced by using a polysaccharide lambda-spirulinan at least containing rhamnose, mannose, uronic acid and N-acetyl sugar as constituent components and produced by Spiruline. The agent has low side effect and strong carcinostatic activity. The lambda-spirulinan used as an active component is soluble in an aqueous solution of potassium chloride and can be derived from a spirulinan composed of lambda-spirulinan and kappa-spirulinan which is insoluble in an aqueous solution of potassium chloride. It is preferably administered parenterally (e.g. pertoneal infusion, intravenous injection, intramuscular injection, rectal infusion, etc.). Dose: 20-0.01mg/kg daily, preferably 2-0.1mg/kg daily. It can be administered for a long period, every 1-5 days.
PURPOSE:To prevent the effect of an accidental change in the output of a gas sensor on a detection threshold value, by setting the detection threshold value from the histogram of the past output of the gas sensor and detecting gas from the comparison of the output of the gas sensor with the detection threshold value. CONSTITUTION:In such a case that the detection threshold value J is set on the basis of the past output of a gas sensor 4 and the gas is detected from the comparison of the output 1 of the gas sensor 4 with the detection threshold value J, the detection threshold value J is set from the histogram of the past output of the gas sensor 4. In the conversion of the histogram to the detection threshold value J, for example, the sensor output corresponding to the max. frequency of the histogram, the sensor output corresponding to the median of the histogram or the average value of the sensor output calculated from the histogram is used. In order to calculate the detection threshold value, it is pref. to pay attention to the max. frequency of the histogram. Even when the output of the sensor is varied by an accidental cause, the sensor output is not varied.
Background: A bidirectional association between shape and weight concerns (SWC) and physical activity (PA) has been previously documented. This relationship may be particularly salient among youth with overweight/obesity, given that social marginalization of larger bodies has been associated with elevated SWC and barriers to PA. This pilot study explores reciprocal relationships between momentary SWC and accelerometer-assessed PA behavior. Methods: Youth with overweight/obesity (N = 17) participated in a 14-day ecological momentary assessment protocol, during which they were prompted to respond to questions about SWC several times per day. They also continuously wore Actiwatch 2 accelerometers to capture light and moderate-to-vigorous PA behavior. Results: Hierarchical linear modeling revealed a unidirectional association between SWC and PA, whereby after engaging in a higher duration of PA, participants reported lower SWC. SWC did not predict subsequent PA. Conclusion: The findings support a negative temporal relationship between PA and SWC. While further work is needed to replicate and extend these preliminary findings, they may suggest that PA acutely benefits SWC among youth with overweight and obesity.